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A B S T R A C T
Breast cancer is a serious public health problem that causes thousands of deaths annually. Chemotherapy
continues to play a central role in the management of breast cancer but is associated with extreme off-target
toxicity. Therefore, treatments that directly target the tumor and display reduced susceptibility to resistance
could improve the outcome and quality of life for patients suffering from this disease. Photodynamic therapy is a
targeted treatment based on the use of light to activate a photosensitizer (PS) that then interacts with molecular
oxygen and other biochemical substrates to generate cytotoxic levels of Reactive Oxygen Species. Currently
approved PS also tends to have poor aqueous solubility that can cause problems when delivered intravenously.
In order to circumvent this limitation, in this manuscript, we evaluate the potential of a phthalocyanine-loaded
nanostructured lipid carrier (NLC) functionalized with folic acid (FA). To prepare the FA labelled NLC, the
polymer PF127 was first esterified with FA and emulsified with an oil phase containing polyoxyethylene 40
stearate, capric/caprylic acid triglycerides, ethoxylated hydrogenated castor oil 40 and the PS zinc phthalo-
cyanine. The resulting PS loaded FA-NLC had a hydrodynamic diameter of 180 nm and were stable in suspension
for> 90 days. Interestingly, the amount of singlet oxygen generated upon light activation for the PS loaded FA-
NLC was substantially higher than the free PS, yet at a lower PS concentration. The PS was released from the NLC
in a sustained manner with 4.13 ± 0.58% and 27.7 ± 3.16% after 30min and 7 days, respectively. Finally,
cytotoxicity assays showed that NLC in the concentrations of 09.1 μM of PS present non-toxic with> 80 ± 6.8%
viable and after 90 s of the light-exposed the results show a statistically significant decrease in cell viability
(57 ± 4%). The results obtained allow us to conclude that the functionalized NLC incorporated with PS asso-
ciated with the PDT technique have characteristics that make them potential candidates for the alternative
treatment of breast cancer.
1. Introduction
Innovative research is being focused on alternative strategies for the
treatment of breast cancer, including the Photodynamic Therapy (PDT).
PDT was approved for a number of clinical indications (Barret's eso-
phagus, esophageal, endobronchial, and non-small cell lung cancers) by
the FDA and has been tested to treat breast cancer in several studies,
with promising results for controlling the recurrence rate [1,2].
PDT is based on oxidative photochemical reactions, requiring a
photoactive compound, called photosensitizer (PS) and light of an ap-
propriate wavelength [3]. This association (PS+ light), in the presence
of ground state oxygen, results in the generation of significant amounts
of reactive oxygen species (ROS), including singlet oxygen, hydrogen
peroxide (H2O2) and hydroxyl radicals (%OH). These ROS induce mul-
tiple pathways of cellular and tissue damage, including DNA damage
and membrane damage, that may lead to apoptosis or necrosis, and (but
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not limited to) vascular damage, compromising the tumor blood supply
[4]. More importantly, the photodynamic reaction only takes place
where the light is delivered, which makes PDT a highly selective
therapy.
Therefore, unlike conventional cancer therapies (surgery, radio-
therapy and chemotherapy), PDT is a minimally invasive therapy
modality with minimum or no side effects; can be repeated without
dose-limiting toxicity or inducible resistance; results in little or no
scarring; can often be administered in the outpatient setting, and is not
contraindicated with other therapy modalities [5].
Thus, hematoporphyrin derivatives (Photofrin II®) were the first
generation of PS; however, they exhibit low absorption in red light and
cause skin photosensitivity as an adverse reaction. The use of second-
generation PS such as the phthalocyanines bring numerous advantages
to PDT, such as high purity and low toxicity, as well as high light ab-
sorption in the red region of the electromagnetic spectrum (the range in
which light penetrates deeper into the tissue) [6,7]. However, these
compounds are lipophilic molecules, which hinder their solubility in
physiological medium and prevent the exploitation as potential PS [8].
In that sense, an attractive strategy to overcome these disadvantages
is the incorporation of phthalocyanine PS into nanostructured lipid
carriers (NLCs). NLCs are characterized by having a lipid matrix of
imperfect crystals stabilized by surfactants, providing spaces for the
incorporation of high concentrations of hydrophobic active substances
[9]. In addition, its lipophilic properties result in better targeting to-
wards the cancer cells [10].
The selectivity of the NLC for the tumor can be further improved by
the functionalization of the carrier with a targeting moiety. Folic acid
(FA) is commonly used for this purpose due to the difference in folate
receptors expression between normal and tumor cells: the receptors are
expressed in low amounts by healthy cells, and in large quantities by a
variety of tumor cells (ovary, prostate and breast, for example) [11–13].
In this context, the use of FA-functionalized NLC as a PS carrier for
PDT can be a promising nanobiotechnological tool for the treatment of
tumors that overexpress the folate receptor, such as breast cancer.
Hence, the aim of this study was to develop and characterize FA-
functionalized NLC carrying a second-generation PS (NLC-FA-PS) and
to evaluate its photochemical and photodynamic properties for future
applications in the treatment of breast cancer.
2. Methods
2.1. Synthesis of PF127-FA
The functionalization of synthetic polymer Pluronic F127® (PF127)
with FA was based on the synthesis developed by Lin et al. [14]. In-
itially, 87.58mg of FA (Mw=441.404 g/mol, Sigma-Aldrich) and
70.64mg of 1,1′‑carbonyldiimidazole (Mw=162.15 g/mol, Sigma-Al-
drich (CDI)) were dissolved in 3mL of dimethyl sulfoxide (DMSO) and
added to a round bottom flask. The reaction remained under stirring
(500 rpm) and inert atmosphere of N2 for 24 h. Subsequently, 0.62 g of
PF127 (Mw~12,500, Sigma), previously dried (overnight) in a vacuum
oven, were added. The reaction was maintained under N2 atmosphere
and stirred for 24 h. The product was dialyzed in deionized water for
4 days using cellulose membrane (molecular weight cut-off=14,000,
Sigma-Aldrich, 76mm). The water was changed every 3 h. PF127-FA
was recovered by lyophilization (48 h). All processes were carried out
in the absence of light.
2.2. Fourier transform infrared spectroscopy (FTIR)
Bruker Vertex 70ATR infrared spectrometer using the 4 cm−1 re-
solution, with scan time of 64 s, from 4000 to 400 cm−1 was used to
perform Infrared spectrometric analysis of the FA, PF127 and PF127-
FA. Samples were diluted with KBr, using 148mg of KBr and 2mg of
the sample.
2.3. Nuclear magnetic resonance (NMR)
1H NMR analysis of FA, PF127 and PF127-FA were recorded in
deuterated dimethylsulfoxide (DMSO-d6) using a Bruker Avance III 600
spectrometer, equipped with a 5mm cryogenic probe.
2.4. Quantification of FA content
The efficacy of PF127-FA synthesis was performed following the
methodologies previously described [15,16]. FA (5mg) was pre-dis-
solved in 10mL of DMSO and then diluted in 40mL of ultra-pure water
to achieve a stock solution of 100 μg/mL.
The detection was performed at 365 nm using a UV–visible spec-
trophotometer (Cary 60 UV–Vis, Agilent Technologies) and the stan-
dard curve with concentrations between 5 and 70 μg/mL was obtained.
The value of the equation of the line was:
= =y x0.0133 0.0185 R 0.9905.2 (1)
The content of folate conjugated to Pluronic F127® was estimated
based on the calibration curve of free FA, using the same UV–visible
conditions, assuming a similar molar absorbance for the free FA and the
conjugated molecule.
2.5. Development of the NLC functionalized with FA
The development of the NLC was based on the work conducted by
SATO et al. [9], with modifications. Briefly, the selected formulation
was composed of 2.07% (w/w) polyoxyethylene 40 (EP) stearate,
2.05% (w/w) capric/caprylic acid triglycerides (TGACC), and 0.88%
(w/w) ethoxylated hydrogenated castor oil 40, in the lipid phase, and
3.5% (w/w) of PF127 functionalized with FA and deionized water in
the aqueous phase. The aqueous phase was added onto the molten lipid
phase under constant stirring, forming a pre-emulsion. The dispersion
of the pre-emulsion was performed by sonication with an amplitude of
35%, in discontinuous mode of 4min with intervals of 30 s every 60 s,
700W of power and a probe of 1/16 in diameter.
Subsequently, the formulations were centrifuged at 5000 rpm for
10min in order to verify their stability and eliminate the released ti-
tanium of the probe and the supernatant were packed in amber bottles
and kept at 4 °C.
The photosensitizer (Zinc 1,2,3,4,8,9,10,11,15,16,17,18,22,23,24,25-
hexadecafluoro-29H,31H-phthalocyanine) used in this study was com-
mercially purchased from Sigma-Aldrich and added at the lipid phase
with final concentration of 280 μM.
2.6. Encapsulation efficiency determination
PS-NLC obtained was centrifuged at 4800 rpm for 30min. After, the
supernatant was filtered (0.45 μm), using cellulose acetate Minisart®
NML filters to separate any non-encapsulated precipitate drug from
encapsulated drug. The amount of PS loaded was quantified using Cary
Eclipse Fluorescence Spectrophotometer at 677 nm with excitation at
639 nm (slit width of 5 nm). The concentration of PS was calculated by
means of a standard calibration curve derived for known concentrations
of ZnPc (0.125–2 μg/mL). Thus, PS encapsulation efficiency was cal-
culated as follows:
= ×EE M /M 1001 T
where EE is the PS encapsulation efficiency, M1 the mass of PS in NLC,
and MT the mass of PS used in the formulation [17].
2.7. Hydrodynamic diameter (d.nm), polydispersity index (PDI) and zeta
potential (ZP) of FA-NLC
The average hydrodynamic diameter (d.nm), polydispersity index
(PDI) and zeta potential (ZP) of the FA-NLC were performed by
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dynamic light scattering (DLS) and electrophoretic light scattering, at
25 °C, in a Zetasizer Nano NS equipment (Malvern Instruments,
Malvern, UK). Samples were previously diluted in ultra-pure water
(1:1000, v/v) for the analysis. Five measurements were performed for
each analysis, and the results were expressed by the average of obtained
values and the standard deviation. To check for the stability, formula-
tions were analyzed at times intervals of 1, 7, 15, 21, 30, 45, 60 and
90 days.
2.8. Transmission electron microscopy (TEM)
Transmission electron microscopy was performed using a JEOL
JEM-100CX2 transmission electron microscope. The preparation of the
sample consisted of adding a small aliquot in the nickel grate, followed
by the removal of the excess sample by filter paper. The negative
contraction was then performed by the addition of one drop of 1% (m/
v) uranyl acetate solution in the sample. After 10min, the excess liquid
was removed, and the sample was dried at room temperature. The
samples were analyzed under a microscope at a voltage of 100 kV.
2.9. Photobleaching
PS samples (free PS dissolved in tetrahydrofuran; and NLC-FA-PS)
were irradiated by a 660 nm LED device (IrradLED® — biopdi, Sao
Carlos, SP, Brazil) using an irradiance of 100mW/cm2 and 1-minute
intervals, to a total of 10min. Between each irradiation the absorbance
spectra of the samples were recorded (Synergy H1 Multi-Mode Reader,
BioTek, Winooski, VT, USA).
2.10. Singlet oxygen generation in cell free systems (SOSG)
To a solution of SOSG (2.5 μM) in methanol (1.750mL) was added
to the PS-NLC (0.250mL (0.125mg of PS)). The solution was exposed to
light for 10min (Fenix LD01 LED, 50mW output,113.0 J/cm2) and the
fluorescence intensity of SOSG (upon excitation at 505 nm) was re-
corded at 525 nm at 5-minute intervals. The protocol was performed for
the following groups (i) PS alone, (ii) PS+ light, (iii) NLC-FA, (iv) NLC-
FA+ light, (v) NLC-FA-PS and (vi) NLC-FA-PS+ light.
2.11. In vitro drug release studies
The direct dialysis method was used for PS in vitro drug release
studies. Aliquots of 1mL of NLC containing PS were enclosed in
SnakeSkin™ Dialysis Tubing (Mw cut-off of 3500, Thermo Scientific,
Rockford, USA) and dispersed in 50mL of n-octanol (medium), main-
tained at 37 °C and stirred with a magnetic stirrer at a constant rate of
500 rpm. At given time intervals, 700 μL samples were withdrawn and
the same amount of fresh medium was replaced. The released PS was
quantified by fluorescence emission (λEX=639 nm; λEM=678 nm).
The in vitro release profile was obtained by correlating time (h) versus
drug release (%). For comparison, the free PS was tested. For this, a PS
mass was weighed and suspended in a small volume of medium, then
the drug suspension was placed inside the dialysis pouch and the ana-
lysis performed as previously mentioned.
2.12. MTT assay
The breast cancer cell line MCF-7 was cultured in bottles with
Dulbecco's Modified Eagle's Medium (DMEM) containing high glucose
(4.5 g/L) and supplemented with 10% fetal bovine serum and 1% of the
penicillin-streptomycin mixture, maintained in a 5% CO2 incubator at
37 °C until the cell monolayer was confluent (70%). The cells were then
washed with 10ml of PBS solution and trypsinized, adding 5ml of ATV
(Association of Trypsin (0.2%) and Versene (0.02%)). The 100 μL of cell
suspension (5× 104 cells/mL) were seeded in 96-well plates and after
24 h incubation, the medium was discarded and the cells were treated
with a 100 μL suspension of NLC-FA-PS in three different concentra-
tions 9.1, 1.82 and 0.91 μM of PS.
After 30min, selected wells were treated with light using an LED
light source (Fenix LD01 LED, 50mW output,113.0 J/cm2) and 4
treatment times (30, 60, 90 and 120 s). Untreated cells and cells treated
with light only were used for comparative purposes. After 24 h, cellular
metabolic activity was assessed using a MTT (4,5-dimethyl-2-thiazolyl)
-2,5-diphenyl-2H-tetrazolium bromide (MTT, Sigma, USA) assay. Thus,
the medium was discarded and 10 μL of solution of PBS containing MTT
(5mg/mL) was added to each well and incubated at 37 °C, protected
from light for 3 h. Finally, 100 μL of DMSO was added in each well and
the spectrophotometric reading of the absorbance at wavelength
570 nm was performed on plate reader (FLUOstar Omega, BMG
LABTECH).
3. Results and discussions
3.1. Synthesis of PF127 with FA
In the pre-formulation study for the NLC development, the PF127
was selected as the surfactant, based on its ability to sensitize multi-
drug-resistant cells which overexpress efflux proteins as P-glycoprotein
and multidrug resistance-associated proteins [18]. As described pre-
viously, FA was chosen to increase the selectivity of the NLCs to
ovarian, prostate and breast tumor cells. FA has high attraction for the
cellular overexpressed receptor (Kd= 1 nM), in addition, is a low cost,
biocompatible and low molecular weight (441 Da) molecule. Those
features allow for better diffusion through biological barriers (when
compared to antibodies used in functionalization), and consequently,
improves the internalization of molecules that would be naturally im-
permeable to the cell membrane via the endocytosis process [19,20].
Previous studies focused on the synthesis of a compound of PF127
with FA demonstrated that at a molar ratio of 1:4, at least one of the
two hydroxyl groups (OH) present in PF127 was linked to the FA car-
boxylic acid group (HOeC]O) by a covalent bond. In addition to
providing a molecular targeting mechanism to FR positive cells, the
covalent ester bond between PF127 and FA should also remain stable in
circulation and only be hydrolyzed by endogenous esterase enzymes
following cellular uptake [14].
The conjugation reaction involved first generating the active ester of
FA (FA-DCI) using carbodiimide chemistry followed by addition of
PF127 to form the ester between the FA and P127. Fig. S1 shows the
schematic illustration of these reactions and an image of the material
obtained, which was a yellow powder obtained in 54.18%.
3.2. Nuclear magnetic resonance and FTIR techniques
To prove that the covalent ester bond between PF127 and FA was
formed, infrared spectroscopy and nuclear magnetic resonance techni-
ques were used.
3.2.1. FTIR
Fig. 1 shows the infrared spectra for PF127 and the product ob-
tained from the reaction between PF127 and FA. It was possible to
observe the presence of a band at 1720 cm−1, corresponding to the
ester carbonyl stretch (R-COOR).
In addition, all bands of interest found for compound PF127-FA
(522.23, 848.44, 954.32, 1124.82, 1287.54, 1345.15, 1467.38,
1605.19, 1703.17, 1971.88, 2354.93 and 2884.34 cm−1) are in ac-
cordance with the bands found in the work of Lin et al. [14].
The IR spectrum from FA is mainly characterized by the C]O
stretching vibrations (1665 cm1), the bending mode of the NeH group
(1605 cm1) and the absorption of the phenyl ring (1460 cm1).
Thus, through the infrared spectrometry technique, the formation of
the product PF127-FA can be suggested, because unlike polymer
(PF127), this compound has a characteristic band of the ester linkage.
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3.2.2. Nuclear magnetic resonance
The 1H NMR spectra of FA, the polymer PF127 and the synthesis
product PF127-FA, are shown in Figs. S2, S3 and S4 available in sup-
plementary information.
The 1H NMR spectrum of the FA (S2) showed the characteristic
signals of the aromatic ring protons δ 8.65–7.65 and the methylene
protons at δ 4.47. The broad residual peak at δ 3.33 refers to the re-
sidual peak water in the sample.
For better understanding, a comparison of PF127-FA product data
(S4) was done with the 1H NMR data obtained by Lin et al. [14].
The comparison shows that the peaks are similar. In addition, we
can identify the specific peaks of the clusters present in the isolated
compounds. 1H NMR analysis of the product was dominated by the
large resonance at 3.5 ppm attributed to the methylene protons of the
POE block of the PF127 component. However, expansion of the aro-
matic region did reveal resonances attributed to the FA aromatic pro-
tons. Using a process of relative integration, and assuming an average
molecular weight for PF127 of ~12,500 Da, it was estimated that 69%
of PF127 was labelled with FA and this is similar to that obtained by Lin
et al. in previous studies [14].
3.3. Folate determination in the conjugate PF127-FA
FA concentration in the sample was 40 μg/mL, the absorption was
0.075; consequently, based on the amount of FA in the beginning of the
synthesis and in the yield of the process, for each 1mg of PF127, about
0.176mg of FA was conjugated. Therefore, based on the theoretical
calculation, 77.03% of FA was linked to the reactive groups of the
PF127.
3.4. Preparation of the functionalized NLCs
The preparation of the functionalized NLC was performed according
to the methodology developed by Sato et al. [9]. These authors tested
20 formulations varying the concentration of PF127 in 1, 2, 2.5, 3, 3.5
and 4%, dispersing the pre-emulsion by sonication with an amplitude of
8%, in discontinuation mode of 20min with interval of 30 s. The results
showed that all NLCs formed with 3.5% PF127 had a mean hydro-
dynamic diameter of< 112 nm, and PDI of< 0.2, indicating that the
particles are homogeneously distributed (monodisperse).
However, high sonication times lead to greater contamination of the
formulation by the metals of equipment [21]. Therefore, an amplitude
of 35% and a time of 4min were used in this work. The increase in the
amplitude resulted in a superior increase of the probe temperature,
obtaining particles in the nanometric scale and, consequently, the
formation of a more homogeneous system [22].
Fig. S5 shows the visual characteristics for the NLC-FA with or
without PS and illustrates its spatial distribution.
The NLC-FA exhibited well-defined macroscopic characteristics:
yellow coloration, without precipitate, and no creaming process or
phase separation occurs for as long as 90 days. The addition of PS (blue
in color) causes a change in NLC coloration to green; however, stability
of the macroscopic characteristics is maintained as observed for NLC
without a drug.
3.5. Incorporation of PS into NLCs and encapsulation efficiency
determination
The incorporation of PS into the NLC was performed concomitantly
with the lipid phase preparation step. This method causes the retention
and dispersion of the PS (hydrophobic character) within the lipid phase
by hydrophobic-hydrophobic interactions.
It was possible to determine macroscopically that concentrations of
PS > 280 μM formed precipitates, thus it was not completely dispersed
or solubilized into the NLC.
The formation of precipitates is a drawback of these photo-
sensitizers, due to their hydrophobicity and tendency to aggregate in
aqueous medium, which reduces their availability for ROS [23]. How-
ever, after the centrifugation and filtration procedures the encapsula-
tion efficiency corresponded to 63.00 ± 1.19% for formulation NLC-
FA.
The encapsulation efficiency can be considered high, since different
nanosystems described in the literature (polymer nanoparticle, solid
lipid nanoparticle, micelles, liposomes and others) are not able to so-
lubilize and incorporate such amount of PS or hydrophilic molecules
[24–26].
3.6. Hydrodynamic diameter (Z-ave or d.nm), PDI and ZP of FA-NLC
The physical stability of NLC depends on its size and ZP. In addition,
NLC with nanometer size are advantageous for the treatment of tumors
since solid tumors accumulate and retain particles between 100 and
780 nm, a phenomenon denominated as enhanced permeability and
retention (EPR) effect [27].
The results of d.nm, PDI and ZP of the NLC-FA and NLC-FA-PS are
shown in Fig. 2.
The NLC-FA without PS produced values of d.nm from
152.2 ± 0.97 nm to 166.7 ± 1.33 nm, with PDI values ranging from
0.21 ± 0.0091 to 0.14 ± 0.018 and ZP −17 ± 1.18mV to
−16.4 ± 0.45mV over the course of 90 days. Whereas, NLC-FA-PS
produced values of d.nm from 165.3 ± 2.34 nm to 181.3 ± 0.99 nm.
For these samples, the PDI values range from 0.23 ± 0.014 to
0.18 ± 0.012 and ZP −17.3 ± 0.74mV to −19.9 ± 1.32mV over
the course of 90 days.
DLS results show that values of mean diameter, ZP and PDI were
similar over the 90 days. In addition, the incorporation of PS in this
concentration did not modify the distribution profile of d.nm, during
the 90 days of storage, indicating homogeneity of the particles. The
negative values of ZP are related to the ionization of OH or COOH
groups present in the components used and are responsible for avoiding
the nanoparticle agglomeration during storage time due to electrostatic
repulsive forces [28]. The low values of standard deviation indicate a
good reproducibility of the method.
Moreover, the results of mean diameter are similar to those found in
the literature for NLC [9], thus the use of a larger amplitude (35%) and
a shorter sonication time (4min) has been shown to be effective.
3.7. Transmission electronic microscopy (TEM)
TEM is a technique used to verify the morphology and particle size
at the nanoscale and is important to confirm the results of the DLS.
Fig. 1. Recorded infrared spectra of the product obtained from pure PF127, FA
and from the reaction between FA and PF127.
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The results of TEM reveal that NLC-FA (Fig. 3a) and NLC-FA-PS
(Fig. 3b) have spherical morphology with nanometer sizes between 50
and 300 nm, similar to the sizes found in the DLS particle distribution
graph.
Moreover, by analyzing the amplified NLC-FA-PS particle, it was
possible to observe the incorporation of the PS by means of the dark
contracture caused by the metal present in the PS, as mentioned in the
step of incorporation, PS (liposoluble) by hydrophobic/hydrophobic
bond would be dispersed in the imperfect crystals of the lipid matrix.
3.8. Photobleaching
It is important that the nanosystem does not interfere with the PS
photobleaching profile. If the nanosystem increases the photobleaching
rate, then the PS will not be available long enough after light activation,
reducing its efficiency in generating ROS. Otherwise, a higher con-
centration of the PS would be necessary to be administered to com-
pensate for the loss [29].
Fig. 4 shows the photobleaching rate of the pure PS (THF solution)
and all the nanosystems. The PS concentration in all samples was
500 μg/mL. It is clear that the final formulation, NLC-FA-PS, protected
the PS from photobleaching, an important feature to guarantee efficient
photodynamic reactions.
Free PS spectrum (Fig. 4a) showed after 2min a rapid decrease in
the absorbance intensity when exposed to light at 671 nm. After 6min
of irradiation, a 56% decrease was observed but then remained rela-
tively stable, whereas when incorporated into the NLC-FA, the photo-
bleaching rate was reduced to 25% after 6min. These results demon-
strate that the incorporation of PS in NLC not only reduced the
photobleaching rate but it also enables its dispersion in aqueous buffer.
3.9. SOSG results
Singlet oxygen production is related to the photodynamic activity.
Thus, singlet oxygen production was estimated via SOSG assay to verify
if the PS-loaded in NLC could modify the singlet oxygen production in
relation to the free PS. SOSG is non-fluorescent but when bleached by
singlet oxygen produces a fluorescent substrate. The results of percen-
tage increase in fluoresce intensity of SOSG are shown in Fig. 5.
Free PS and NLC-FA-PS produced the same increase in percentage of
SOSG emission until 10 min, 63.34% ± 8.05 and 61.89% ± 2.25, re-
spectively and significant increase in relation to PS and NLC-FA-PS
without light. The NLC-FA with or without light does not show any
increase in SOSG emission.
3.10. In vitro drug release studies
The use of n-octanol was necessary to ensure sink conditions, since
the PS is extremely insoluble in water. This medium was adapted from
previous publications and it has similarity to lipophilicity of biological
membranes [30,31]. Pure PS was used as control for comparisons in the
release profile aiming to understand the dose released from the nano-
particle (Fig. 6).
The results reveal that NLC-FA did not reveal a burst effect but
exhibited a sustained release of the PS showing 4.13 ± 0.58% and
27.7 ± 3.16% after 30min and 7 days, respectively; whereas, free PS
exhibited 32.09 ± 4.13% and 83.66 ± 6.9% of drug release, after
30min and 24 h, respectively. This behavior can be associated with
NLC which are composed of a mixture of liquid and solid lipids forming
imperfect crystalline structures, which results in larger drug in-
corporation spaces, and better incorporation efficiency compared to
other nanosystems, preventing its expulsion. Moreover, the sustained
Fig. 2. Results of d.nm, PDI and ZP to NLC-FA (a) and NLC-FA-PS (b) directly after preparation and after 7, 15, 21, 30, 45, 60 and 90 days, n=3.
Fig. 3. TEM images of the nanocarriers (a) NLC-FA and (b) NLC-FA-PS, at magnification of 20,000× and 100,000×, respectively.
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release, in combination with the higher resistance to photobleaching,
means there is potential for one administration of the PS loaded NLC-FA
to be used for multiple treatments [32].
3.11. MTT assay
Cytotoxicity assays are highly utilized since they reduce the need for
laboratory animals, provide a quick indication of efficacy and are low
cost.
Fig. 7 shows the plot of cell viability (%) for MCF-7 cells line fol-
lowing treatment with (i) untreated, (ii) light only, (iii) NLC-FA, (iv)
NLC-FA-PS in three different concentrations (0.91, 1.82 and 9.1 μM)
without light, (v) NLC-FA-PS (0.91 μM) in four different light exposure
times(30, 60, 90 and 120 s).
First, we investigated the NLC-FA-PS on MCF-7 cell viability in the
three concentrations of 0.91, 1.82 and 9.1 μM in absence of light. The
results showed that until 0.91 μM they are non-toxic with>80 ±
6.8% viable. When NLC-FA-PS (0.91 μM) was irradiated for 120 s, the
viability decreases to 57 ± 4% which was statistically significant
(Fig. 7).
4. Conclusion
With this research, it was possible to conclude that the synthesis
Fig. 4. Curves of the fluorescence intensity as a function of time for (a) PS in THF at the concentration of 500 μg/mL and (b) the photobleaching rate for PS and NLC-
FA-PS.
Fig. 5. Curves of the percentage increase in SOSG emission as a function of time
for PS, NLC-AF and NLC-AF-PS after different treatments: in the dark as a
control (no light), and after LED light (50mW output, 113.0 J/cm2). Error bars
represent± the standard error where n=3.
Fig. 6. In vitro drug release profiles of free PS and NLC-FA-PS. The experiments
were performed in n-octanol at 37 °C.
Fig. 7. Plot of cell viability (%) for MCF-7 cells line following treatment with (i)
untreated, (ii) light only, (iii) NLC-FA, (iv) NLC-FA-PS in three different con-
centrations (0.91, 1.82 and 9.1 μM) without light, (v) NLC-FA-PS (0.91 μM) in
four different times of exposure to light (30, 60, 90 and 120 s). *p < 0.05,
**p < 0.01, ***p < 0.001, ns: no significant difference. Error bars re-
present± the standard error, n=3.
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between FA and PF127 was performed efficiently. Subsequently, using
this molecule, it was possible to develop a new PS loaded NLC with a
mean size of< 180 nm which is ideal to passive target in tumors by
EPR effect. In addition, the PS chosen has high light absorption in the
red region. The light penetration in the tissues is directly proportional
to its wavelength (λ) reaching up to 16.0mm at λ from 700 to 900 nm.
Thus, the treatment could be conducted for tumors within this depth
without microsurgery for light probe introduction. Besides that, the
sustained release showed the potential for one administration of the PS
loaded NLC-FA to be used for multiple treatments. Finally, the photo-
bleaching results did not alter the photobleaching profile of PS, whereas
NLC exerted a protective effect on PS, so it is possible to use a smaller
amount of drug producing high concentrations of ROS. MTT assay
showed that NLC in the concentrations of 0.91 μM of PS presented a
significant reduction after 90 s of the light-exposed in cell viability
(57 ± 4%). The results obtained allow us to conclude that the func-
tionalized NLC incorporated with PS associated with the PDT technique
have characteristics that make them potential candidates for the al-
ternative treatment of breast cancer.
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